Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.26)
# 2,693
Out of 5,124 analysts
53
Total ratings
30%
Success rate
4.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Initiates: Overweight | n/a | $7.55 | - | 1 | Dec 18, 2025 | |
| NVAX Novavax | Initiates: Overweight | $18 | $7.44 | +141.94% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.69 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $1.90 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $93.21 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $46.52 | +114.96% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $4.02 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $6.61 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.28 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $15.75 | - | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.10 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.88 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $36.20 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.91 | +161.78% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.96 | +563.27% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $19.75 | -59.49% | 1 | Mar 20, 2023 |
CervoMed
Dec 18, 2025
Initiates: Overweight
Price Target: n/a
Current: $7.55
Upside: -
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $7.44
Upside: +141.94%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.69
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.90
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $93.21
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $46.52
Upside: +114.96%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.02
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.61
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.28
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.75
Upside: -
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.10
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.88
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $36.20
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.91
Upside: +161.78%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $1.96
Upside: +563.27%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $19.75
Upside: -59.49%